Tag: Lifastuzumab Vedotin
Lifastuzumab Vedotin is Well-tolerated + Improves Objective Response Rate in Phase...
Lifastuzumab vedotin, also known as DNIB0600A (RO5541081) and RG-7599, is an antibody-drug conjugate or ADC.
In clinical trials the investigational drug is compared to pegylated...
FDA Clears Mersana’s IND Application for XMT-1536
Focusing on discovering and developing a pipeline of novel antibody-drug conjugates or ADCs based on its proprietary Dolaflexin® platform, Mersana Therapeutics' Investigational New Drug...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
Novel Targeted Lung Cancer Therapies are Expected to Replace Current Conventional...
Lung cancer, which is mostly a disease of the elderly*, is defined as the uncontrolled growth of abnormal cells in one or both lungs. Approximately 60%...
ADC Market to Reach US$ 3 Billion by 2018
According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...
